The 2012 BIO International Convention was a success!
My speakers and I were fortunate to have been interviewed by BIO regarding our breakout session on Systems Biology and how this approach will lead us to discover drugs with better efficacy and fewer side effects based on patient phenotypes or subclasses of patients bringing us closer to personalized medicine.
To view the Systems Biology presentation and each speaker’s interview, click on the videos below.
Regina Au is a Strategic Marketing Consultant at BioMarketing Insight specializing in the biotechnology, pharmaceutical, medical device, and diagnostic industries. She helps companies evaluate their technology upfront by conducting the business due diligence in de-risking the product development process. more
|David E. Hill, Ph.D., is a Principal Research Scientist in Cancer Biology and Associate Director of the Center for Cancer Systems Biology (CCSB) at the Dana-Farber Cancer Institute (DFCI). CCSB explores biological processes relevant to cancer from a systems point of view. The overall goal of CCSB….more|
|Dr. J. Carl Barrett is Vice President of Translational Science in the Oncology Innovative Medicines Unit at AstraZeneca Pharmaceuticals. His responsibility is to develop and execute biomarker strategy and translational sciences efforts to support compound development from research…more|
|Nikolai Kley, Ph.D., is Founder and Vice President of Discovery Biology for Forma Therapeutics. Prior to joining FORMA, Dr. Kley was Vice President and Head of Research at GPC Biotech. Dr. Kley was an early member of the GPC Biotech management team (1999-2007) and played key roles in developing and advancing the company’s genomics, …more|
|Candida Fratazzi, M.D., is a Clinical Strategy and Trial Design Specialist with over 25 years of experience. She is a recognized expert in the development of Orphan indications and Rare Disease clinical trial designs. Dr. Fratazzi is President at Boston Biotech Clinical Research, LLC (BBCR) since 2009. more|